Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
7 Rock-Solid Healthcare Dividend Stocks to Buy in January
09:10am, Saturday, 06'th Jan 2024
The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventi
Are defensive sectors ready to outshine growth in 2024?
07:50am, Saturday, 06'th Jan 2024
The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NA
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
07:50am, Saturday, 06'th Jan 2024
AbbVie is a Dividend King that should soon return to growth. Bristol Myers Squibb boasts an impressive streak of dividend hikes and a promising pipeline.
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)
06:48pm, Thursday, 04'th Jan 2024
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)
3 Dividend Stocks for Strong Returns in 2024 and Beyond
03:27pm, Thursday, 04'th Jan 2024
The S&P 500 closed out a strong year, up more than 20% for 2023. For investors looking for the best dividend stocks in the New Year and beyond, we recommend companies with durable competitive advantag
7 Stocks Primed for a Spectacular Comeback in 2024
06:17pm, Wednesday, 03'rd Jan 2024
While investors might be tempted to ride the biggest winners of last year, shifting sands may provide a superior outlook for comeback stocks. Just what am I talking about?
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
03:47pm, Wednesday, 03'rd Jan 2024
Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.
Bristol-Myers Squibb downgraded on mixed sales performance of new products amid loss of exclusivity concerns
02:05pm, Wednesday, 03'rd Jan 2024
Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) has been downgraded by Bank of America (BoA) analysts given the mixed performances of the drugmaker's newly launched products and lack of clarity
Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
02:49am, Sunday, 31'st Dec 2023
Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Since 2019, Bristol-Myers Squibb has acquired pharmaceutical companies worth more than $115 billion, allowing
Here are the 20 worst-performing stocks among the S&P 500 in 2023
11:18am, Friday, 29'th Dec 2023
The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.
10 Dividend Growth Stocks: December 2023
09:00am, Friday, 29'th Dec 2023
In my monthly series of 10 Dividend Growth Stocks, I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for further research and possible investment.
Bristol Myers Squibb's big buys: $18.1 billion in 2 biotech deals
08:39am, Friday, 29'th Dec 2023
On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc. NASDAQ: KRTX for $330 per share in cash, for a total equity value of $14 billion.
Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth Knowing
07:35pm, Thursday, 28'th Dec 2023
The latest trading day saw Bristol Myers Squibb (BMY) settling at $51.22, representing a +0.02% change from its previous close.
5 Upcoming Dividend Increases To Start 2024, Including A Dividend King
04:41pm, Thursday, 28'th Dec 2023
ABM Industries extends its 56-year streak of dividend increases with a 2.3% increase.
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
12:01pm, Wednesday, 27'th Dec 2023
Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.
